Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of PomDoctor Ltd. securities, alleging fraudulent activities during the Class Period from October 9, 2025, to December 11, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [5]. - It is alleged that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that PomDoctor's public statements omitted critical information regarding false rumors and artificial trading activity [5]. - The lawsuit asserts that the misleading statements made by the defendants about PomDoctor's business and prospects caused investors to suffer damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased PomDoctor securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must be appointed by April 7, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - The complaint against PomDoctor alleges violations of federal securities laws, including false statements and undisclosed fraudulent activities related to stock promotions and insider trading [2]. Group 1: Allegations Against PomDoctor - The complaint claims that PomDoctor was involved in a fraudulent stock promotion scheme utilizing misinformation on social media and impersonation of financial professionals [2] - It is alleged that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [2] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [2] - As a result of these actions, the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought and is responsible for directing the litigation on behalf of the class [3] - Any member of the putative class has the option to move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3] Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding PomDoctor's conduct, including whistleblowers and former employees, to contact the firm [4]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against PomDoctor Ltd. (NASDAQ: POM) on behalf of investors who purchased securities between October 9, 2025, and December 11, 2025, alleging that the company misled investors regarding its business operations [1]. Group 1: Allegations Against PomDoctor Ltd. - The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1]. - As a result of these actions, the positive statements made by the defendants about PomDoctor's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by April 7, 2026 [1]. - A lead plaintiff acts on behalf of other class members in directing the litigation, but participation is not required to be eligible for recovery [1]. - All representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [1].

("Scott+Scott†), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP (collectively, the "Defendants†). The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. PomDoctor Ltd. et al., Ca. NEW YORK--(BUSINESS WIRE)---- $POM #POM--Scott+Scott Attorneys at L ...

ATLANTA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Pomdoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (ii) insiders and/or affiliates used of ...

GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical companies to accelerate the growth of its internet hospital business. The Company expects these partnerships to become a core component of its long-term strategy to expand online hospital operations and enhance overall p ...

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. has reported a significant investment loss of nearly 300 million yuan due to a 90% drop in the stock price of its investment in Guangzhou Qilokang Digital Health Medical Technology Co., Ltd. after the IPO of its substantial holding, Pomdoctor Limited, on NASDAQ [1][2] Group 1: Investment Loss - The company announced an expected fair value change loss of 293 million yuan related to its investment in Qilokang Digital Medical [1] - As of September 30, 2025, the book value of the investment was 326 million yuan, but the stock price plummeted after the IPO [2] - The IPO price of Pomdoctor Limited was set at 4.00 USD per share, but the closing price dropped to 0.2949 USD per share by December 31, 2025 [2] Group 2: Inventory Crisis - The company is facing an inventory crisis with a total inventory of 4.517 billion yuan, of which approximately 12% is involved in a legal dispute [2] - There is a risk of needing to recognize inventory impairment provisions related to the 550 million yuan dispute, which could impact current and future profits [2] - The lawsuit concerning the inventory has been accepted by the court but has not yet gone to trial, leaving the outcome uncertain [2] Group 3: Company Background - Shandong Buchang Pharmaceutical Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company is located in Heze City, Shandong Province, with a registered capital of approximately 1.054 billion yuan [2]

| 代码 | 名称 | 最新价 | 涨跌幅 √ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | STEC | 三合智能 | 1.5300 | 59.38% | +0.5700 | 3107.75万 | | HIHO | 骇维金属加工 | 1.2500 | 50.60% | +0.4200 | 2.61亿 | | POM | 石榴云医 | 0.3499 | 30.95% | +0.0827 | 323.61万 | | NAMI | 进馨科技 | 0.8098 | 22.53% | +0.1489 | 11.2万 | | XHG | XChange TEC | 1.1200 | 22.10% | +0.2027 | 10.31万 | 格隆汇12月24日｜中概股收盘涨幅居前的个股为：三合智能涨59.38%，骇维金属加工涨50.6%，石榴云 医涨30.95%，进馨科技涨22.53%，XChange TEC涨22.1%。(格隆汇) ...

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with 东方文化 experiencing the largest drop of 89.53% [1] - 东方文化's latest price is 0.911, with a decrease of 7.789 and a trading volume of 46.57 million [1] - 明珠货运 saw a decline of 61.57%, with its latest price at 0.0216, a drop of 0.0346, and a trading volume of 3.96 million [1] - ChowChow Cloud Inte's stock fell by 38.80%, with a current price of 1.120, a decrease of 0.710, and a trading volume of 9.92 million [1] - 逸仙电商's stock price decreased by 30.91%, currently at 3.890, down by 1.740, with a trading volume of 6.13 million [1] - 石榴云医 experienced a decline of 23.12%, with a latest price of 0.3844, a drop of 0.1156, and a trading volume of 4.69 million [1]

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Wok Medical dropping by 96.59% and Pomegranate Cloud Medical by 90.77% [1] - ChowChow Cloud Inte experienced a decline of 84.36%, while Reto Eco fell by 34.15% and Zhongchi Chefu decreased by 26.37% [1] - The trading volumes for these stocks were notable, with Wok Medical having a transaction amount of 40.03 million and Pomegranate Cloud Medical at 28.88 million [1]